In a major medical breakthrough, Novartis has received approval for the world’s first malaria drug designed specifically for newborns and infants, offering new hope in the fight against childhood malaria.
Early-stage oral cancer achieves 80–90% five-year survival - with surgery, radiotherapy, chemo, and rehab, patients can restore function and quality of life.
